menu search

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor biomarker reduction (77%) with 32% having complete clearance Robust mKRAS-specific T cell responses induced in 87% of patients BOSTON, June 03, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company […] The post Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeu... Read More
Posted: Jun 3 2023, 13:00
Author Name: forextv
Views: 091912

Search within

Pages Search Results: